Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $8.30 USD
Change Today +0.19 / 2.34%
Volume 891.8K
BCRX On Other Exchanges
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Jon P. Stonehouse

Chief Executive Officer, President and Executive Director, BioCryst Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 24 board members in 3 different organizations across 4 different industries.

See Board Relationships
As of Fiscal Year 2013


Mr. Jon P. Stonehouse has been the Chief Executive Officer of BioCryst Pharmaceuticals, Inc. at Shionogi & Co., Ltd. since joining in January 8, 2007 and also has been its President since July 13, 2007. Mr. Stonehouse has over 20 years strong commercialization, Financial transaction, Business development and Management experience. Previously, he served as Senior Vice President of Corporate Development of Merck KGaA., since July 2002 and was responsible for global licensing ...

Read Full Background

Corporate Headquarters*

4505 Emperor Boulevard
Durham, North Carolina 27703

United States

Phone: 919-859-1302
Fax: 919-859-1314

Board Members Memberships*

Chief Executive Officer, President and Executive Director
Director, Chairman of Compensation Committee and Member of Audit Committee


University of Minnesota

Other Affiliations*

Annual Compensation*

Total Annual Compensation$475,716

Stock Options*

Restricted Stock Awards$88,892
All Other Compensation$13,655
Exercised Options179,600
Exercised Options Value$84,412
Exercisable Options875,560
Exercisable Options Value$1,449,500
Unexercisable Options598,990
Unexercisable Options Value$2,968,371
Total Value of Options$4,717,283
Total Number of Options1,754,150

Total Compensation*

Total Annual Cash Compensation$655,872
Total Short Term Compensation$475,716
Other Long Term Compensation$102,547
Total Calculated Compensation$1,975,287
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BCRX:US $8.30 USD +0.19


Gustav A. Christensen Chief Executive Officer, President and Director
Dyax Corp.
John C. Martin Ph.D.Chairman and Chief Executive Officer
Gilead Sciences Inc.
Flemming Ornskov M.D., MBA, MPHChief Executive Officer, Managing Director and Director
Shire plc
Thomas W. D'Alonzo Esq., J.D.Chairman, Acting Chief Executive Officer, Acting President, Member of Audit Committee, Member of Nominating/Corporate Governance Committee and Member of Compensation Committee
Salix Pharmaceuticals Ltd.
Joji Nakayama Chief Executive Officer, President and Representative Director
Daiichi Sankyo Company, Limited
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOCRYST PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at